BETTER MEDICINE
FOR ALL.

We make drugs efficient through long-acting injectables.

Learn more

 
 
 
 

Fast expanding portfolio

Already 3 programs in Clinical

PRECLINICAL & CLINICAL DEVELOPMENT

As of february, 2020

As of December, 2020


IMPACT HEALTH

People

130+ people, all shareholders, driven to impact health

Who we are

Business model

Building a global pharma leader through long-acting injectables working with NGOs, Private Sector, and Academics

Our network

Technology

We’ve broken every barrier to enabling long-acting injectable adoption

BEPO®

Meet us

Our news

Meet us

Our news

Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin

Corporate

04/19/2021

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

CorporateInvestors

12/17/2020

MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations

Investors

12/09/2020

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date

Corporate

11/12/2020

See all

 
 

Who we are

Who we are

Our strength is our people

MedinCell is operated by our talented employees who have come together from around the world to achieve our mission of Better Medicine for All.
Through purposeful innovation, we aim to improve the treatments available to patients. And we believe that everyone should have access to best-in-class medication, so we focus on making our products available regardless of local economic conditions. To ensure access, we work on both for-profit and non-profit projects, in collaboration with highly valued partners ranging from big pharmas to physicians, from biotech firms to academics and foundations. Most importantly, our partners share our values based on trust and transparency.

Who we are

Careers

CONTACT

  • This field is for validation purposes and should be left unchanged.